Ketotifen (systemic): Drug information

For abbreviations, symbols, and age group definitions used in Lexicomp (show table)

Brand Names: Canada

Zaditen

Pharmacologic Category

Histamine H₁ Antagonist;
Histamine H₁ Antagonist, Second Generation;
Mast Cell Stabilizer;
Piperidine Derivative

Dosing: Pediatric

Atopic asthma

Atopic asthma (prophylactic treatment): Oral:

Infants and Children 6 months to 3 years: Initial: 0.05 mg/kg once daily or in 2 divided doses for 5 days; Maintenance: 0.05 mg/kg/dose twice daily (maximum dose: 1 mg twice daily)

Children >3 years and Adolescents: Initial: 1 mg once daily or in 2 divided doses for 5 days; Maintenance: 1 mg twice daily

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer's labeling.

Dosing: Hepatic Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer's labeling.

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Reported adverse reactions are for children and adolescents, unless otherwise noted.

1% to 10%:

Dermatologic: Skin rash (4%)

Endocrine & metabolic: Weight gain (5%)

Gastrointestinal: Abdominal pain (1%), increased appetite (1%)

Infection: Influenza (3%)

Nervous system: Sleep disturbance (1%)

Ophthalmic: Eyelid edema (1%)

Respiratory: Epistaxis (1%), respiratory tract infection (4%)

Frequency not defined: Hepatic: Increased liver enzymes

Postmarketing (any age):

Dermatologic: Erythema multiforme, Stevens-Johnson syndrome

Gastrointestinal: Nausea (Maclay 1984), xerostomia (Maclay 1984)

Genitourinary: Cystitis

Hypersensitivity: Hypersensitivity reaction

Nervous system: Central nervous system stimulation (including excitement, insomnia, irritability, nervousness), dizziness (Maclay 1984), drowsiness (Maclay 1984), headache (Maclay 1984), sedated state (Maclay 1984), seizure

Contraindications

Hypersensitivity to ketotifen or any component of the formulation; use of ketotifen syrup in patients sensitive to benzoate compounds

Warnings/Precautions

Concerns related to adverse effects:

• Hypersensitivity: Hypersensitivity reactions have occurred.

• Sedation: May cause drowsiness early in therapy; initiate therapy at one-half the recommended daily dose and gradually increase over 5 days to maintenance dose; patients must be cautioned about performing tasks which require mental alertness. (eg, operating machinery or driving).

• Thrombocytopenia: Rare cases of thrombocytopenia have been reported in patients concurrently using oral ketotifen and oral antidiabetic agents; manufacturer labeling does not specify associated agents but recommends to monitor platelet counts in patients receiving concomitant therapy.

Disease related concerns:

• Epilepsy: Use with caution in epileptic patients; may lower seizure threshold. Seizures have been reported rarely during therapy.

Special populations:

• Diabetics: Due to the carbohydrate content of the syrup preparation, diabetic patients may need to use tablet.

Dosage form specific issues:

• Benzoate allergy: Syrup products may contain benzoate compounds.

Other warnings/precautions:

• Appropriate use: Indicated for prophylactic treatment; not effective for the prevention or treatment of acute bronchospasm. Therapy with agents used for prophylaxis or relief of asthma related symptoms (eg, corticosteroids, beta₂-agonists, xanthine derivatives), should be maintained for at least 6 to 12 weeks and then gradually reduced as clinically indicated. An immediate increase in corticosteroid dosage may be necessary in patients with severe relapse of symptoms during corticosteroid dose reduction; assess adrenal and pituitary function prior to initiating corticosteroid dose reduction in patients who have received long term therapy Steroid-dependent patients with adrenocortical insufficiency can take up to one year to recover a normal stress related pituitary-adrenal response.

• Delayed clinical response: Therapeutic effects may not be clinically evident until several weeks after the initiation of therapy; maximum effectiveness usually requires duration of therapy ≥10 weeks. Therapy should be maintained for at least 2 to 3 months to determine effectiveness. If therapy requires discontinuation, gradually reduce over 2 to 4 weeks.

Product Availability

Not available in the US

Generic Equivalent Available: US

May be product dependent

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product

Syrup, Oral:

Zaditen: 0.2 mg/mL ([DSC]) [contains alcohol, usp, methyl hydroxybenzoate, propyl hydroxybenzoate]

Tablet, Oral:

Zaditen: 1 mg

Administration: Pediatric

Oral: Administer without regards to meals.

Syrup: Use the measuring device that comes with this drug or a calibrated measuring device.

Use: Labeled Indications

Note: Not approved in the United States.

Atopic asthma: Adjunctive therapy in the chronic treatment of mild, atopic asthma in pediatric patients ([syrup], ≥5 years of age [tablets]).

Limitations of use: Not indicated for relief of acute bronchospasm.

Medication Safety Issues

Sound-alike/look-alike issues:

Ketotifen may be confused with ketoprofen

Zaditen may be confused with Zaditor

Metabolism/Transport Effects

None known.

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.

Acetylcholinesterase Inhibitors: May diminish the therapeutic effect of Anticholinergic Agents. Anticholinergic Agents may diminish the therapeutic effect of Acetylcholinesterase Inhibitors. Risk C: Monitor therapy

Aclidinium: May enhance the anticholinergic effect of Anticholinergic Agents. Risk X: Avoid combination

Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl). Risk C: Monitor therapy

Alizapride: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Amantadine: May enhance the anticholinergic effect of Anticholinergic Agents. Risk C: Monitor therapy

Amezinium: Antihistamines may enhance the stimulatory effect of Amezinium. Risk C: Monitor therapy

Anticholinergic Agents: May enhance the adverse/toxic effect of other Anticholinergic Agents. Risk C: Monitor therapy

Azelastine (Nasal): May enhance the CNS depressant effect of CNS Depressants. Risk X: Avoid combination

Benzylpenicilloyl Polylysine: Antihistamines may diminish the diagnostic effect of Benzylpenicilloyl Polylysine. Management: Suspend systemic H1 antagonists for benzylpenicilloyl-polylysine skin testing and delay testing until systemic antihistaminic effects have dissipated. A histamine skin test may be used to assess persistent antihistaminic effects. Risk D: Consider therapy modification

Betahistine: Antihistamines may diminish the therapeutic effect of Betahistine. Betahistine may diminish the therapeutic effect of Antihistamines. Risk C: Monitor therapy

Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin. Management: Use caution if coadministering blonanserin and CNS depressants; dose reduction of the other CNS depressant may be required. Strong CNS depressants should not be coadministered with blonanserin. Risk D: Consider therapy modification

Botulinum Toxin-Containing Products: May enhance the anticholinergic effect of Anticholinergic Agents. Risk C: Monitor therapy

Brexanolone: CNS Depressants may enhance the CNS depressant effect of Brexanolone. Risk C: Monitor therapy

Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Bromopride: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Bromperidol: May enhance the CNS depressant effect of CNS Depressants. Risk X: Avoid combination

Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine. Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine at lower doses in patients already receiving CNS depressants. Risk D: Consider therapy modification

Cannabinoid-Containing Products: Anticholinergic Agents may enhance the tachycardic effect of Cannabinoid-Containing Products. Risk C: Monitor therapy

Cannabinoid-Containing Products: CNS Depressants may enhance the CNS depressant effect of Cannabinoid-Containing Products. Risk C: Monitor therapy

Chloral Betaine: May enhance the adverse/toxic effect of Anticholinergic Agents. Risk C: Monitor therapy

Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used. Risk D: Consider therapy modification

Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants. Risk C: Monitor therapy

Chlorprothixene: Anticholinergic Agents may enhance the anticholinergic effect of Chlorprothixene. Risk C: Monitor therapy

Cimetropium: Anticholinergic Agents may enhance the anticholinergic effect of Cimetropium. Risk X: Avoid combination

CloZAPine: Anticholinergic Agents may enhance the constipating effect of CloZAPine. Management: Consider alternatives to this combination whenever possible. If combined, monitor closely for signs and symptoms of gastrointestinal hypomotility and consider prophylactic laxative treatment. Risk D: Consider therapy modification

CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants. Risk C: Monitor therapy

Daridorexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dose reduction of daridorexant and/or any other CNS depressant may be necessary. Use of daridorexant with alcohol is not recommended, and the use of daridorexant with any other drug to treat insomnia is not recommended. Risk D: Consider therapy modification

DexmedeTOMIDine: CNS Depressants may enhance the CNS depressant effect of DexmedeTOMIDine. Management: Monitor for increased CNS depression during coadministration of dexmedetomidine and CNS depressants, and consider dose reductions of either agent to avoid excessive CNS depression. Risk D: Consider therapy modification

Difelikefalin: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Doxylamine: CNS Depressants may enhance the CNS depressant effect of Doxylamine. Risk C: Monitor therapy

DroPERidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (eg, opioids, barbiturates) with concomitant use. Risk D: Consider therapy modification

Eluxadoline: Anticholinergic Agents may enhance the constipating effect of Eluxadoline. Risk X: Avoid combination

Esketamine: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Flunarizine: CNS Depressants may enhance the CNS depressant effect of Flunarizine. Risk X: Avoid combination

Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam. Management: Reduce the dose of CNS depressants when combined with flunitrazepam and monitor patients for evidence of CNS depression (eg, sedation, respiratory depression). Use non-CNS depressant alternatives when available. Risk D: Consider therapy modification

Gastrointestinal Agents (Prokinetic): Anticholinergic Agents may diminish the therapeutic effect of Gastrointestinal Agents (Prokinetic). Risk C: Monitor therapy

Glucagon: Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased. Risk C: Monitor therapy

Glycopyrrolate (Oral Inhalation): Anticholinergic Agents may enhance the anticholinergic effect of Glycopyrrolate (Oral Inhalation). Risk X: Avoid combination

Glycopyrronium (Topical): May enhance the anticholinergic effect of Anticholinergic Agents. Risk X: Avoid combination

Hyaluronidase: Antihistamines may diminish the therapeutic effect of Hyaluronidase. Risk C: Monitor therapy

HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants. Management: Consider a decrease in the CNS depressant dose, as appropriate, when used together with hydroxyzine. Increase monitoring of signs/symptoms of CNS depression in any patient receiving hydroxyzine together with another CNS depressant. Risk D: Consider therapy modification

Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergic Agents. Risk X: Avoid combination

Itopride: Anticholinergic Agents may diminish the therapeutic effect of Itopride. Risk C: Monitor therapy

Ixabepilone: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Kava Kava: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Kratom: May enhance the CNS depressant effect of CNS Depressants. Risk X: Avoid combination

Lemborexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dosage adjustments of lemborexant and of concomitant CNS depressants may be necessary when administered together because of potentially additive CNS depressant effects. Close monitoring for CNS depressant effects is necessary. Risk D: Consider therapy modification

Levosulpiride: Anticholinergic Agents may diminish the therapeutic effect of Levosulpiride. Risk X: Avoid combination

Lisuride: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Lofexidine: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants. Management: Reduce the usual dose of CNS depressants by 50% if starting methotrimeprazine until the dose of methotrimeprazine is stable. Monitor patient closely for evidence of CNS depression. Risk D: Consider therapy modification

Metoclopramide: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. Risk C: Monitor therapy

Mianserin: May enhance the anticholinergic effect of Anticholinergic Agents. Risk C: Monitor therapy

Minocycline (Systemic): May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Mirabegron: Anticholinergic Agents may enhance the adverse/toxic effect of Mirabegron. Risk C: Monitor therapy

Nabilone: May enhance the CNS depressant effect of CNS Depressants. Risk X: Avoid combination

Nitroglycerin: Anticholinergic Agents may decrease the absorption of Nitroglycerin. Specifically, anticholinergic agents may decrease the dissolution of sublingual nitroglycerin tablets, possibly impairing or slowing nitroglycerin absorption. Risk C: Monitor therapy

Olopatadine (Nasal): May enhance the CNS depressant effect of CNS Depressants. Risk X: Avoid combination

Opioid Agonists: CNS Depressants may enhance the CNS depressant effect of Opioid Agonists. Management: Avoid concomitant use of opioid agonists and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug. Risk D: Consider therapy modification

Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. Risk X: Avoid combination

Oxatomide: May enhance the anticholinergic effect of Anticholinergic Agents. Risk X: Avoid combination

Oxomemazine: May enhance the CNS depressant effect of CNS Depressants. Risk X: Avoid combination

Oxybate Salt Products: CNS Depressants may enhance the CNS depressant effect of Oxybate Salt Products. Management: Consider alternatives to this combination when possible. If combined, dose reduction or discontinuation of one or more CNS depressants (including the oxybate salt product) should be considered. Interrupt oxybate salt treatment during short-term opioid use Risk D: Consider therapy modification

OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE. Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug. Risk D: Consider therapy modification

Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. Risk X: Avoid combination

Perampanel: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. Risk C: Monitor therapy

Pitolisant: Antihistamines may diminish the therapeutic effect of Pitolisant. Risk X: Avoid combination

Potassium Chloride: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride. Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride. Risk X: Avoid combination

Potassium Citrate: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Citrate. Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium citrate. Risk X: Avoid combination

Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. Risk C: Monitor therapy

Pramlintide: May enhance the anticholinergic effect of Anticholinergic Agents. These effects are specific to the GI tract. Risk X: Avoid combination

Procarbazine: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Ramosetron: Anticholinergic Agents may enhance the constipating effect of Ramosetron. Risk C: Monitor therapy

Revefenacin: Anticholinergic Agents may enhance the anticholinergic effect of Revefenacin. Risk X: Avoid combination

Rivastigmine: Anticholinergic Agents may diminish the therapeutic effect of Rivastigmine. Rivastigmine may diminish the therapeutic effect of Anticholinergic Agents. Management: Use of rivastigmine with an anticholinergic agent is not recommended unless clinically necessary. If the combination is necessary, monitor for reduced anticholinergic effects. Risk D: Consider therapy modification

Ropeginterferon Alfa-2b: CNS Depressants may enhance the adverse/toxic effect of Ropeginterferon Alfa-2b. Specifically, the risk of neuropsychiatric adverse effects may be increased. Management: Avoid coadministration of ropeginterferon alfa-2b and other CNS depressants. If this combination cannot be avoided, monitor patients for neuropsychiatric adverse effects (eg, depression, suicidal ideation, aggression, mania). Risk D: Consider therapy modification

ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. Risk C: Monitor therapy

Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. Risk C: Monitor therapy

Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced. Risk C: Monitor therapy

Secretin: Anticholinergic Agents may diminish the therapeutic effect of Secretin. Management: Avoid concomitant use of anticholinergic agents and secretin. Discontinue anticholinergic agents at least 5 half-lives prior to administration of secretin. Risk D: Consider therapy modification

Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant. Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary. Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended. Risk D: Consider therapy modification

Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. Risk X: Avoid combination

Thiazide and Thiazide-Like Diuretics: Anticholinergic Agents may increase the serum concentration of Thiazide and Thiazide-Like Diuretics. Risk C: Monitor therapy

Tiotropium: Anticholinergic Agents may enhance the anticholinergic effect of Tiotropium. Risk X: Avoid combination

Topiramate: Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate. Risk C: Monitor therapy

Trimeprazine: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Umeclidinium: May enhance the anticholinergic effect of Anticholinergic Agents. Risk X: Avoid combination

Valerian: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem. Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for men who are also receiving other CNS depressants. No such dose change is recommended for women. Avoid use with other CNS depressants at bedtime; avoid use with alcohol. Risk D: Consider therapy modification

Zuranolone: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to the use of zuranolone with other CNS depressants or alcohol. If combined, consider a zuranolone dose reduction and monitor patients closely for increased CNS depressant effects. Risk D: Consider therapy modification

Pregnancy Considerations

Adverse events have been observed in some animal studies.

Breastfeeding Considerations

Breast-feeding is not recommended by the manufacturer.

Dietary Considerations

Syrup contains carbohydrate 4 g/5 mL.

Monitoring Parameters

Manufacturer labeling recommends monitoring of platelet counts in patients receiving oral antidiabetic agents.

Mechanism of Action

Exhibits noncompetitive H₁-receptor antagonist and mast cell stabilizer properties. Efficacy in asthma likely results from a combination of anti-inflammatory and antihistaminergic actions including interference with chemokine-induced migration of eosinophils into inflamed airways, inhibition of airway hyper-reactivity due to platelet activating factor (PAF), antagonism of leukotriene-induced bronchoconstriction.

Pharmacokinetics (Adult Data Unless Noted)

Absorption: Rapid, almost complete.

Protein binding: ~75%.

Metabolism: Hepatic via N-glucuronidation to inactive metabolite ketotifen-N-glucoronide; N-demethylation to active metabolite nor-ketotifen; and keto-reduction to hydroxyl derivative.

Clearance: Increased in children >3 years; decreased in children ≤3 years.

Bioavailability: ~50%.

Half-life elimination: Biphasic: Distribution: 3 to 5 hours; Elimination: 21 hours.

Time to peak, plasma: 2 to 4 hours.

Excretion: Urine (>60% as metabolites, 1% as unchanged drug).

Brand Names: International

International Brand Names by Country

For country code abbreviations (show table)

(AE) United Arab Emirates: Asmafort | Gloditen | Histofen | Ketonil | Zaditen;
(AR) Argentina: Ketocev | Ketokid | Respimex | Structum | Zaditen;
(AT) Austria: Ketotisan | Zaditen;
(BD) Bangladesh: Aerofen | Airnaaf | Asmafen | Deneral | Fenat | Ketasma | Ketifen | Ketof | Ketomar | Ketopac | Ketorif | Ketosma | Ketotif | Kofen | Ktin | Minia | Orotifen | Prosma | S kit | Sesofen | Stafen | Tifen | Tifsi | Tofen | Toti | Totifen | Zaditen;
(BE) Belgium: Ketotifen teva generics belgium | Ketotiphar | Zaditen;
(BG) Bulgaria: Ketotifen | Zaditen;
(BR) Brazil: Amistofeno | Asdron | Asmalergin | Asmanon | Asmen | Asmifen | Asmofen | Biatos | Broncoten | Fumarato de cetotifeno | Nemesil | Profilasmin-ped | Uni cetotifen | Zaditen | Zetitec;
(CH) Switzerland: Zaditen | Zaditen mit bananenaroma;
(CL) Chile: Ketotisin | Zadetin;
(CN) China: Ketotifen;
(CO) Colombia: Asmiket | Caytin | Difen | Ketobron | Ketofar | Ketofen | Ketotifeno | Ketotifeno MK | Mediket | Pulmofen | Zaditen | Zidox;
(CZ) Czech Republic: Ketof | Zaditen;
(DE) Germany: Astifat | Ketof | Ketofex | Ketotifen | Ketotifen beta | Ketotifen stada | Ketotifen-ratiopharm | Zaditen | Zatofug;
(DO) Dominican Republic: Alertax | Baykid ketotifeno | Cipanfeno | Fortifeno | Kasmal | Ketifen | Ketonal | Ketotifeno | Ketotifran | Nor-Tifeno | Pretifen | Zaditen;
(EC) Ecuador: Kasmal | Ketonal | Ketotifeno | Ketotifeno Ecar | Ketotifeno la sante | Ketotifeno MK | Tifen | Zaditen;
(EE) Estonia: Ketotifen | Zaditen;
(EG) Egypt: Allerban | Ketoti | Ketotifen | Prophallerge | Zaditen | Zedotefen | Zylofen;
(ES) Spain: Zasten;
(ET) Ethiopia: Ketotifen;
(FR) France: Zaditen;
(GB) United Kingdom: Zaditen;
(GR) Greece: Demetofrin | Eucycline | Frenasma | Klevistamin | Labelphen | Orpidix | Pellexeme | Zaditen;
(HK) Hong Kong: Amitone | Asmafen | Asthan | Astifen | Axcel ketotifen | Dhatifen | Erletin | Eumofen | Ketifen | Ketotifen | Qualitifen | Xidanef | Zaditen;
(HU) Hungary: Ketotifen l.f.m. | Zaditen;
(ID) Indonesia: Astifen | Intifen | Ketotifen | Nortifen | Pehatifen | Prevas | Profilas | Scanditen | Tosma | Zaditen;
(IE) Ireland: Zaditen;
(IL) Israel: Profiten | Zaditen;
(IN) India: Airyfen | Asthafen | Azofen | Ketasma | Ketotif | Ketovent | Mastifen | Privent | Stafen | Tritofen | Zerosma;
(IQ) Iraq: Ketofen | Ketohist | Ketotifen | Ketotifen mdi | Kinotefen | Kotifen awa | Zadofen;
(IT) Italy: Alleal | Allerket | Chetofen | Chetotifene | Ketotifene eg | Zaditen;
(JO) Jordan: Ketonil | Profilar | Tefanyl | Totinal | Zaditen;
(JP) Japan: Ketotifen | Ketotifen nichiiko | Mellabon | Saldimen | Saldimen amel | Sekiton | Supdel | Xeblen | Zaditen;
(KE) Kenya: Ketomar | Ketotif | Tofen | Zaditen;
(KR) Korea, Republic of: Algina | Allermin | Altifen | Astifen | Brongtiphen | Brontipen | E-ten | Edifen | Fumatifen | Iten | Jensma | Karifen | Kediran | Kediton | Kepiten | Kerofu | Ketasma | Keten | Ketomin | Ketoten | Ketotifen | Ketotifen daewon | Ketotifen fumarate seoul | Konifen | Kopufen | Laditen | Lotifen | Marfen | Matigen | Nazalen | Panaben | Pumatifen | Ratis | Sama ketotifen | Samsung ketotifen fumarate | Tamon | Tanodin | Tegifen | Tifenal | Zaditen | Zaspan;
(KW) Kuwait: Asmafort | Histofen | Zaditen;
(LB) Lebanon: Zaditen;
(LT) Lithuania: Asthafen | Denerel | Ketasma | Ketof | Ketotifen | Klevistamin | Zaditen;
(LU) Luxembourg: Ketof | Zaditen;
(LV) Latvia: Asthafen | Denerel | Ketasma | Ketotifen | Zaditen;
(MA) Morocco: Nekar | Totifen;
(MX) Mexico: Asmaral-k | K asmal | Kasmal | Ketaxal | Ketotifeno | Nomotec-t | Osaten | Pretifen | Zaditen;
(MY) Malaysia: Asmafen | Asmaten | Asumalife | Axcel ketotifen | Denerel | Dhatifen | Eucycline | Ketifen | Ketotifen | Licoften | Sykofen | Tritofen | U-Kefen | Zaden | Zadimin | Zadipro | Zaditen | Zynaten;
(NG) Nigeria: Zaditen;
(NL) Netherlands: Ketotifen | Zaditen;
(NO) Norway: Zaditen;
(NZ) New Zealand: Asmafen | Zaditen | Zasten;
(PE) Peru: Ketonil | Ketotifeno | Ketotifeno genfar | Ketotifeno pentacoop | Ketotisin | Zaditen;
(PH) Philippines: Dhatifen | Quomyl | Totifen | Zadec | Zaditen;
(PK) Pakistan: Aktofen | Aria | Asfen | Asmofen | Asperfin | Asthanil | Asthonex | Asthotifen | Avofen | Caltek | Deasma | Katifen | Keften | Kehf | Ketfen | Ketoresp | Ketorose | Ketotif | Ketozad | Kotin | Mactifen | Naveten | Proasma | Tifen | Tosma | Totifen | Ventisol | Zag | Zatofen;
(PL) Poland: Ketof | Ketotifen | Pozitan | Zaditen;
(PT) Portugal: Cipanfeno | Quefeno | Zaditen;
(PY) Paraguay: Bronquiasmol | Dilabron | Frenaler | Ketotifeno catedral | Ketotifeno dutriec | Respimex | Ventirene | Zaditen | Zentrol;
(QA) Qatar: Asmafort | Gloditen | Ketoti Pharco | Profilar | Tefanyl | Totinal | Zaditen;
(RO) Romania: Frenasma | H ketotifen | Keto gal | Ketof | Ketotifen | Ketotifen lph | Zaditen;
(RU) Russian Federation: Airyfen | Denerel | Frenasma | Ketasma | Ketotifen | Ketotifen ros | Ketotifen sopharma | Privent | Stafen | Zaditen;
(SA) Saudi Arabia: Asmafort | Gloditen | Histofen | Ketofen | Ketonil | Profilar | Tefanyl | Totinal | Zaditen;
(SG) Singapore: Asumalife | Axcel ketotifen | Denerel | Dhatifen | Ketotifen | Scanditen | Suntotifen | Zaditen;
(SI) Slovenia: Dihalar;
(SK) Slovakia: Denerel | Ketof | Ketotifen | Zaditen;
(TH) Thailand: Allercox | Amitone | Asmafen | Asmanoc | Asthifen | Asumalife | Contifen | Denerel | Fenketo | Ibis | Katifen | Kenefen | Ketasma | Keten | Ketiden | Ketifen | Keto | Ketofen | Ketotab | Ketoten | Ketotifen | Keytifen | Mansofen | Medotifen | Politifen | Servitifen | Startifen | Sukafen | Sykofen | T.M.Fen | Toditen | Totifen | Zadino | Zaditen | Zaten | Zatifen | Zenadine | Zetofen | Zotifen | Zytofen;
(TN) Tunisia: Ketotifene simed | Tefanyl | Totinal | Zaditen;
(TR) Turkey: Astafen | Fumast | Mitofen | Zaditen;
(TW) Taiwan: Asfen | Asthan | Astifen | Asumalife | Athmin | Cofen | Deantran | Denerel | Fusthma | Katifen | Kefen | Kenerlin | Ketifen | Ketimin | Ketofen | Ketoti | Ketotifen | Ketozen | Licoften | Santiten | Soother | Tranlen | Xidanef | Zaditen | Zatizen;
(UA) Ukraine: Frenasma | Ketasma | Ketoborin | Ketotifen | Zaditen;
(UY) Uruguay: Bronquiasmol | Ketalerg | Ketane | Ketonal | Ketotifeno | Respimex | Ventirene | Zaditen;
(VE) Venezuela, Bolivarian Republic of: Cosolve | Ketotifeno | Ketotisin | Musibon | Zaditen;
(ZA) South Africa: Adco-ketotifen | Kefen | Ketohexal | Zaditen | Zetofen;
(ZW) Zimbabwe: Zaditen

Maclay WP, Crowder D, Spiro S, Turner P. Postmarketing surveillance: practical experience with ketotifen. Br Med J (Clin Res Ed). 1984;288(6421):911-914. doi:10.1136/bmj.288.6421.911 [PubMed 6423140]
Zaditen (ketotifen) tablets [product monograph]. Toronto, Ontario, Canada: Teva Canada Limited; October 2022.
Zaditen (ketotifen) tablets and syrup [product monograph]. Toronto, Ontario, Canada: Teva Canada Limited; October 2010.

Topic 16765 Version 190.0

خرید پکیج

Ketotifen (systemic): Drug information